Synthetic antigen-conjugated DNA systems for antibody detection and characterization

Antibodies are among the most relevant biomolecular targetsfordiagnostic and clinical applications. In this Perspective, we providea critical overview of recent research efforts focused on the developmentand characterization of devices, switches, and reactions based onthe use of synthetic antigen-conjugated DNA strands designed to beresponsive to specific antibodies. These systems can find applicationsin sensing, drug-delivery, and antibody-antigen binding characterization.The examples described here demonstrate how the programmability andchemical versatility of synthetic nucleic acids can be used to createinnovative analytical tools and target-responsive systems with promisingpotentials

Clinical Features, Cardiovascular Risk Profile, and Therapeutic Trajectories of Patients with Type 2 Diabetes Candidate for Oral Semaglutide Therapy in the Italian Specialist Care

Introduction: This study aimed to address therapeutic inertia in the management of type 2 diabetes (T2D) by investigating the potential of early treatment with oral semaglutide. Methods: A cross-sectional survey was conducted between October 2021 and April 2022 among specialists treating individuals with T2D. A scientific committee designed a data collection form covering demographics, cardiovascular risk, glucose control metrics, ongoing therapies, and physician judgments on treatment appropriateness. Participants completed anonymous patient questionnaires reflecting routine clinical encounters. The preferred therapeutic regimen for each patient was also identified. Results: The analysis was conducted on 4449 patients initiating oral semaglutide. The population had a relatively short disease duration (42%  60% of patients, and more often than sitagliptin or empagliflozin. Conclusion: The study supports the potential of early implementation of oral semaglutide as a strategy to overcome therapeutic inertia and enhance T2D management

Proceedings Of The 23Rd Paediatric Rheumatology European Society Congress: Part Two

PubMe